Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470076 | 1.00 | CNR2 (0.44) | CNR2MAPTSMN1; SMN2LMNAKDM1A | |
| SCHEMBL20139164 | 0.90 | CNR2 (0.43) | CNR2MAPTSMN1; SMN2LMNACACNA1H | |
| SCHEMBL20154087 | 0.88 | CNR2 (0.42) | CNR2MAPTSMN1; SMN2LMNAKDM1A | |
| SCHEMBL21531620 | 0.77 | CNR2 (0.42) | CNR2SMN1; SMN2CACNA1HTP53ALDH1A1 | |
| SCHEMBL20011907 | 0.77 | GPR119 (0.46) | GPR119 | |
| SCHEMBL30063195 | 0.77 | GPR119 (0.46) | GPR119 | |
| SCHEMBL20012043 | 0.73 | POLB (0.38) | CNR2MAPTSMN1; SMN2LMNAGPR119 | |
| SCHEMBL20139189 | 0.72 | GBA1 (0.38) | CNR2SMN1; SMN2GPR119HTTNPSR1 | |
| SCHEMBL30234939 | 0.72 | GBA1 (0.38) | CNR2SMN1; SMN2GPR119HTTNPSR1 | |
| SCHEMBL30060981 | 0.72 | GBA1 (0.40) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-20220079942-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-03-17 | — | — | US | disclosed |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | disclosed |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | disclosed |
| EP-3538523-B1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3538523-B1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| EP-3538523-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CDC7, CDK7, CDK17 | CNR2 4554/4885MAPT 2853/4885SMN1; SMN2 3498/4885 |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CDC7, CDK7, CDK17 | CNR2 4554/4885MAPT 2853/4885SMN1; SMN2 3498/4885 |
| US-20220079942-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CDC7, CDK7, CDK17 | CNR2 4554/4885MAPT 2853/4885SMN1; SMN2 3498/4885 |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CDC7, CDK7, CDK17 | CNR2 4554/4885MAPT 2853/4885SMN1; SMN2 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.